Industry Supported Symposium 3: BRCA and Beyond: How Cancer Genetic Testing is Evolving in your Practice

Description: Supported by Ambry Genetics Advances in technology now allow for improved diagnosis of hereditary ovarian cancer beyond BRCA. How and when do you offer just BRCA1/2 versus a large multi-gene panel test? During this symposium you will hear from a colleague about his clinical experience using both, clinical implications of findings beyond BRCA, and rationale for when to consider next generation sequencing panels. Ambry was the first lab to offer large multi-gene tests for ovarian cancer and the most up-to-date data will be shared demonstrating the increased yield of panel testing.